Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 50 min ago
Peer-reviewedCC BYReviews in cardiovascular medicine

The Role of Soluble Suppression of Tumorigenicity-2 and Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Scoping Review of the Literature

  • Konstantina Ntalekou1
  • Panagiotis Iliakis1
  • Nikitas Katsillis2
  • Nikolaos Patsourakos2
  • Dimitrios Tsiachris1
  • Dimitrios Farmakis3
  • Polykarpos Christos Patsalis4
  • Christina Chrysohoou1
  • Konstantinos Tsioufis1
4 affiliations
  1. 1First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 11527 Athens, Greece
  2. 2Cardiology Department, “Tzaneio” General Hospital of Piraeus, 18536 Piraeus, Greece
  3. 3Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece
  4. 4Division of Cardiology, Angiology and Internal Emergency Medicine, Department of Medicine, Knappschaft Kliniken University Hospital Bochum, Ruhr University Bochum, 44892 Bochum, Germany
Read full textPDFCite

Related

  1. Dynamic change in soluble suppressor of tumorigenicity 2 (sST2) during acute decompensated heart failure with a reduced ejection fraction, and its mortality implications
    Brian Li, Michaela Dowley, Samantha Langley +7
    American heart journal plus : cardiology research and practicePeer-reviewedCC BY-NC-NDFull textCardiovascular medicineEurope PMC
  2. Galectins and the Interleukin-33/Suppression of Tumorigenicity-2 Pathway in First-episode Psychosis and Schizophrenia: A Cross-sectional Exploratory Study
    Hüseyin Uçar, Meryem Sebla Ertuğrul, Eda Uçar +2
    Clinical Psychopharmacology and NeurosciencePeer-reviewedCC BY-NC 4.0Full textPsychiatry & mental healthPMC
  3. Presumed right atrial myxoma causing mechanical inflow obstruction and a heart-failure-with-preserved-ejection-fraction–mimicking phenotype in a resource-limited setting: A case report
    Radiology case reportsPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  4. Neutrophil-to-Lymphocyte Ratio Identifies a Pulmonary Vascular High-Risk Phenotype in Heart Failure with Preserved Ejection Fraction
    M. Bril, E. Parnasa, A. Sufian +3
    medRxivPreprintAll rights reservedFull textCardiovascular medicinemedRxiv
  5. EASIX for Long-Term Prognostication in Hospitalized Heart Failure with Preserved Ejection Fraction: Incremental Value Beyond Clinical Risk Markers
    Çetin Alak, Kaan Turhan, Fazıl Çağrı Hunutlu +2
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{ntalekou2026role,
  title = {{The Role of Soluble Suppression of Tumorigenicity-2 and Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Scoping Review of the Literature}},
  author = {Konstantina Ntalekou and Panagiotis Iliakis and Nikitas Katsillis and Nikolaos Patsourakos and Dimitrios Tsiachris and Dimitrios Farmakis and Polykarpos Christos Patsalis and Christina Chrysohoou and Konstantinos Tsioufis},
  journal = {Reviews in cardiovascular medicine},
  year = {2026},
  month = sep,
  url = {https://europepmc.org/article/PMC/PMC13653195},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - The Role of Soluble Suppression of Tumorigenicity-2 and Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Scoping Review of the Literature
AU  - Konstantina Ntalekou
AU  - Panagiotis Iliakis
AU  - Nikitas Katsillis
AU  - Nikolaos Patsourakos
AU  - Dimitrios Tsiachris
AU  - Dimitrios Farmakis
AU  - Polykarpos Christos Patsalis
AU  - Christina Chrysohoou
AU  - Konstantinos Tsioufis
PY  - 2026
DA  - 2026/09/01
JO  - Reviews in cardiovascular medicine
UR  - https://europepmc.org/article/PMC/PMC13653195
SN  - 1530-6550
ER  -